Turinabol (4‑Chlorodehydromethyltestosterone)
Oral-Turinabol (Chlorodehydromethyltestosterone, CDMT), 17α-alkylated chlorinated Dianabol-analog oral AAS. Jenapharm 1962, infamous as the main agent of the GDR state doping program 1968-1989 ("Komplex 08"). Notorious for long-term detection metabolites.
The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.
WHAT IS TURINABOL (4-CHLORODEHYDROMETHYLTESTOSTERONE)?
Detailed overview
Turinabol (4-chlorodehydromethyltestosterone, CDMT) is a 17α-alkylated chlorinated Dianabol structural analog oral AAS, synthesized by Jenapharm (East Germany, Jena) in 1962, marketed in 1965 as Oral-Turinabol Rx. It became the MAIN agent of the GDR state doping program ("Staatsplanthema 14.25", Stasi code-named "Komplex 08", 1968-1989); ~10,000+ GDR athletes received Turinabol unknowingly or undocumented, mainly in swimming, athletics, rowing programs. The 1990s Stasi archive openings document the harms (liver damage, cardiomyopathy, virilization in female athletes, neonatal anomalies in doped mothers' children). Anabolic:androgenic ratio 53:6 – high anabolic, virtually zero androgenic ("drier Anavar"). Does NOT aromatize (4-chloro substitution blocks CYP19 substrate binding). 17α-methyl → moderate hepatotoxicity (the 4-chloro reduces it, similar to Anavar). Schänzer 2006 (PMID 17042466) describes extra-long detection metabolites (6β-OH-CDMT and others) – urinary 12-18 month detection is possible, basis of the 2016 Olympic (Rio) IOC re-test: 100+ athletes retrospectively disqualified after 2008-2012 sample re-evaluation. WADA-banned year-round.
Mechanism
AR agonist, 17α-methyl-4-chloro-Δ1-T, NOT aromatized
Anabolic:Androgenic
53:6
Half-life
16 hours (oral)
Onset
2-3 h (oral)
Legal status
Jenapharm Rx (DE) discontinued 1994; UGL today. Schedule III.
Data console
Lab data
Safety
Side effects, stop signs, contraindications
Side effects · 7
- HPTA suppression: endogenous testosterone production shuts down (LH/FSH suppression), testicular atrophy, reduced libido and fertility; prolonged hypogonadism without PCT.
- Adverse lipid changes: moderate-to-marked HDL drop (15-25%) and LDL rise, pronounced with oral 17alpha-alkylated AAS; long-term atherosclerosis risk.
- Hepatotoxicity (oral 17alpha-methyl): ALT/AST elevation 2-3x over 6+ week cycles; clinically milder than Dianabol/Anadrol (4-chloro protection), but liver stress is real, with rare cholestasis and peliosis hepatis.
- Virilization in women: despite the low androgenic ratio, >10 mg/day and longer exposure can cause IRREVERSIBLE voice deepening, clitoral enlargement, hirsutism (documented GDR case: Heidi/Andreas Krieger).
- Elevated blood pressure: hypertension is common during AAS cycles; combined with HDL decline and hematocrit changes it increases cardiovascular load.
- Psychiatric effects: irritability, aggression, mood swings on cycle, plus depression and low libido during cessation/PCT; AAS dependence can develop.
- Androgenic skin effects: acne and oily skin can occur; scalp hair-loss risk is low, however, since Turinabol is not a 5alpha-reductase substrate (no DHT conversion).
Contraindications · 7
- Pregnancy and breastfeeding: absolutely contraindicated due to virilization and risk of fetal developmental abnormalities (the GDR program documented neonatal abnormalities in children of doped mothers).
- Any liver disease or elevated liver enzymes: the 17alpha-methyl group adds hepatic stress, so it must not be used with pre-existing liver impairment.
- Cardiovascular disease, hypertension or adverse lipid profile: HDL decline and raised blood pressure worsen existing cardiovascular risk.
- Hormone-sensitive tumors (prostate or breast carcinoma): contraindicated as an androgen-receptor agonist.
- WADA-tested athletes: extra-long detection window (12-18 months in urine due to Sobolevsky-Rodchenkov 2012 long-term metabolites); to be avoided at any career stage.
- Psychiatric predisposition (depression, bipolar disorder, aggression-control problems): mood side effects and post-cycle depression can exacerbate it.
- Adolescents and growing youths: AAS can cause premature epiphyseal closure and irreversible developmental effects.
Related Performance Compounds
Same therapeutic category
Studies
Related research and clinical findings
Hormonal doping and androgenization of athletes: a secret program of the German Democratic Republic government
Franke WW, Berendonk B.
Detection and mass spectrometric characterization of novel long-term dehydrochloromethyltestosterone metabolites in human urine
Sobolevsky T, Rodchenkov G.
Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement
Pope HG Jr, Wood RI, Rogol A, Nyberg F, Bowers L, Bhasin S.
Effects of androgenic-anabolic steroids in athletes
Hartgens F, Kuipers H.
Anabolic-androgenic steroid dependence: an emerging disorder
Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HG Jr.
Telegram
Have a question about Turinabol (4‑Chlorodehydromethyltestosterone)?
Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.
The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.